{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:06:47Z","timestamp":1790946407217,"version":"4.1.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>Alpha-1 antitrypsin deficiency (AATD) is a prevalent autosomal recessive disorder affecting approximately 3 million people worldwide, caused by mutations in the SERPINA1 gene leading to low alpha-1 antitrypsin (AAT) levels. This deficiency predisposes individuals to chronic obstructive pulmonary disease, bronchiectasis, neonatal cholestasis, and liver cirrhosis. The most common pathogenic mutation, PI*ZZ allele, produces misfolded Z-AAT protein accumulating in hepatocytes. Currently, there are no specific treatments for AATD-related liver disease, with management focusing on preventing complications. Fazirsiran, an investigational RNA interference therapeutic, targets hepatocytes to reduce Z-AAT synthesis. Preclinical studies and an open-label phase 2 trial showed promising results. The subsequent phase 2 SEQUOIA trial, a randomized controlled study, evaluated Fazirsiran\u2019s efficacy and safety in 40 PiZZ homozygous patients. Results demonstrated significant dose-dependent reductions in serum Z-AAT levels (\u221261% to \u221294%) and liver Z-AAT concentrations, improved liver histopathology, and a favorable safety profile. These findings support Fazirsiran\u2019s potential as a therapeutic option for AATD-associated liver disease.<\/jats:p>","DOI":"10.1097\/ms9.0000000000003393","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T14:00:14Z","timestamp":1748527214000},"page":"4014-4016","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Fazirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease findings from the SEQUOIA phase 2 trial"],"prefix":"10.1097","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7707-3577","authenticated-orcid":false,"given":"Talha","family":"Liaquat","sequence":"first","affiliation":[{"name":"Department of Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bareera Tanveer","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7410-7810","authenticated-orcid":false,"given":"Tayyab Habib","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzaifa","family":"Arain","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5076-1364","authenticated-orcid":false,"given":"Mohammad Haris","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Medicine, Shaikh Khalifa Bin Zayed Al-Nahyan Medical College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-5153","authenticated-orcid":false,"given":"Md Ariful","family":"Haque","sequence":"additional","affiliation":[{"name":"Voice of Doctors Research School, Dhaka, Bangladesh"},{"name":"Department of Public Health, Atish Dipankar University of Science and Technology, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"R1-20250922","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1289\/ehp.6511","article-title":"Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed","volume":"111","author":"deSerres","year":"2003","journal-title":"Environ Health Perspect"},{"key":"R2-20250922","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pulmoe.2018.09.004","article-title":"Portuguese consensus document for the management of alpha-1-antitrypsin deficiency","volume":"24","author":"Lopes","year":"2018","journal-title":"Pulmonology"},{"key":"R4-20250922","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/357605a0","article-title":"The mechanism of Z \u03b11-antitrypsin accumulation in the liver","volume":"357","author":"Lomas","year":"1992","journal-title":"Nature"},{"key":"R5-20250922","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/apt.14537","article-title":"Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease","volume":"47","author":"Townsend","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20250922","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/15412555.2013.765839","article-title":"Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy","volume":"10","author":"Teckman","year":"2013","journal-title":"COPD J Chronic Obstruct Pulmon Dis"},{"key":"R8-20250922","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1080\/13543784.2023.2239707","article-title":"RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease","volume":"32","author":"Strnad","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"R9-20250922","doi-asserted-by":"crossref","first-page":"e135348","DOI":"10.1172\/jci.insight.135348","article-title":"Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease","volume":"5","author":"Wooddell","year":"2020","journal-title":"JCI Insight"},{"key":"R10-20250922","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2205416","article-title":"Fazirsiran for liver disease associated with alpha1-antitrypsin deficiency","volume":"387","author":"Strnad","year":"2022","journal-title":"N Engl J Med"},{"key":"R11-20250922","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.gastro.2024.06.028","article-title":"Fazirsiran for adults with alpha-1 antitrypsin deficiency liver disease: a phase 2 placebo controlled trial (SEQUOIA)","volume":"167","author":"Clark","year":"2024","journal-title":"Gastroenterology"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003393","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T07:01:51Z","timestamp":1758524511000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000003393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000003393","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"2025-03-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}